Theralink® Tumor Biomarker Platform
The Theralink® assay technology uses Reverse Phase Protein Array (RPPA) technology to measure the quantity cell surface receptor activity and their downstream signaling pathway activation levels that are drug targets of FDA-approved and investigational therapies. Intended applications include determination of whether a prescribed medication may be effective in treating the right patient at the right time.
Our highly sensitive analyses of identified biomarkers has the potential to empower physicians to improve treatment decisions through better prediction of treatment outcomes. The biomarker information could prevent the patient from being exposed to cytotoxic treatments that may be unlikely to deliver clinically meaningful benefits, while guiding physicians to prescribing treatments that may be likely to yield maximum results.
The Theralink® platform can be used for multiple applications in therapeutic clinical trials including:
- Patient selection
- Patient stratification
- Mechanism Of Action (MOA) examinations
- Pharmacokinetic/pharmacodynamic (PK/PD) end point measurements
Theralink® measures phosphorylated proteins in tumor tissues. Phosphorylated proteins represent active targets for drugs. Examples of tumor indications for application development include:
- Breast Cancer
- Pancreatic Cancer
- Colorectal Cancer
- Non-Small Cell Lung Cancer
However, please inquire with our team about your indication of interest.